Last updated: 10/29/2026 09:20:10

A study to evaluate safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-NHL

GSK study ID
300557
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Trial status
Recruiting
Recruiting
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Trial description: The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.
Primary purpose:
Treatment
Trial design:
Sequential Assignment
Masking:
None (Open Label)
Allocation:
Not applicable
Primary outcomes:

Number of participants with dose limiting toxicities (DLTs)

Timeframe: Up to 28 days

Number of participants with adverse events (AEs) or Serious adverse events (SAEs) by severity

Timeframe: Up to approximately 169 weeks

Secondary outcomes:

Number of participants with clinically meaningful changes in laboratory parameters, vital signs, and electrocardiogram (ECG)

Timeframe: Up to approximately 169 weeks

Overall Response Rate (ORR)

Timeframe: Up to approximately 169 weeks

Maximum concentration (Cmax) of GSK5926371

Timeframe: Up to approximately 169 weeks

Time to Cmax (Tmax) of GSK5926371

Timeframe: Up to approximately 169 weeks

Area under the curve (AUC) of GSK5926371

Timeframe: Up to approximately 169 weeks

Interventions:
Drug: GSK5926371
Enrollment:
49
Primary completion date:
2030-10-01
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Lymphoma, Non-Hodgkin
Product
GSK5926371
Collaborators
Not applicable
Study date(s)
June 2026 to January 2030
Type
Interventional
Phase
1/2

Participation criteria

Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
  • Has histologically confirmed Relapsed/Refractory (R/R) B-NHL, for which systemic treatment is indicated,
  • a) Has measurable disease,
  • Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas (e.g., breast, cervix, bladder) that have been resected with no evidence of metastatic disease.
  • Has had any major surgery within 4 weeks prior to the first dose of GSK5926371 or has not recovered from prior surgeries or complications.

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Tokyo, Japan, 135-8550
Status
Recruiting
Location
GSK Investigational Site
Toronto, ON, Canada, M5G 1X6
Status
Recruiting
Location
GSK Investigational Site
Canton, OH, United States, 44718
Status
Recruiting
Location
GSK Investigational Site
Iowa City, IA, United States, 52242
Status
Recruiting
Location
GSK Investigational Site
Chiba, Japan, 277-8577
Status
Recruiting
Location
GSK Investigational Site
Aichi, Japan, 460-0001
Status
Recruiting
Location
GSK Investigational Site
Heidelberg, VIC, Australia, 3084
Status
Recruiting
Location
GSK Investigational Site
Rozzano, MI, Italy, 20089
Status
Recruiting
Location
GSK Investigational Site
Villejuif Cedex, France, 94805
Status
Recruiting
Location
GSK Investigational Site
Madrid, Spain, 28041
Status
Recruiting
Location
GSK Investigational Site
Valencia, Spain, 46010
Status
Recruiting
Location
GSK Investigational Site
PIERRE BENITE, France, 69495
Status
Recruiting
Location
GSK Investigational Site
Rennes, France, 35033
Status
Recruiting
Location
GSK Investigational Site
Tampere, Finland, 33520
Status
Recruiting
Location
GSK Investigational Site
Madrid, Spain, 28040
Status
Recruiting
Location
GSK Investigational Site
Salamanca, Salamanca, Spain
Status
Recruiting
Location
GSK Investigational Site
Alessandria, Italy, 15121
Status
Recruiting
Location
GSK Investigational Site
BARCELONA, Barcelona, Spain, 08035
Status
Recruiting
Location
GSK Investigational Site
MILANO, Italy, 20133
Status
Recruiting
Location
GSK Investigational Site
Helsinki, Finland, 00290
Status
Recruiting
Location
GSK Investigational Site
New York, NY, United States, 10029
Status
Recruiting
Location
GSK Investigational Site
Barcelona, Spain, 8036
Status
Recruiting

Study documents

No study documents available.

Results overview

Study Results yet to be posted

Recruitment status
Recruiting
Actual primary completion date
Not applicable
Actual study completion date
Not applicable

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website